Xtant Medical Holdings Inc

For the period ended Dec 31, 2023. Filed Apr 1, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 1, 2024

XTNT$0.28-3.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except number of shares and per share amounts)

	Year Ended December 31,
	2023	2022
Revenue
Orthopedic product sales	$91,303	$57,969
Cost of Sales	35,836	25,832
Gross Profit	55,467	32,137
Operating Expenses
General and administrative	25,850	15,462
Sales and marketing	38,439	22,515
Research and development	1,336	915
Total Operating Expenses	65,625	38,892
Loss from Operations	(10,158)	(6,755)
Other Income (Expense)
Interest expense	(2,938)	(1,692)
Interest income	149	31
Unrealized foreign currency translation gain	265	—
Bargain purchase gain	11,694	—
Other expense	(49)	—
Total Other Income (Expense)	9,121	(1,661)
Net Loss from Operations Before Provision for Income Taxes	(1,037)	(8,416)
Benefit (Provision) for Income Taxes Current and Deferred	1,697	(69)
Net Income (Loss)	$660	$(8,485)
Net Income (Loss) Per Share:
Basic	$0.01	$(0.09)
Dilutive	$0.01	$(0.09)
Shares used in the computation:
Basic	119,093,687	94,085,197
Dilutive	126,793,318	94,085,197

Consolidated Statements of Comprehensive Income (Loss)

(In thousands)

	Year Ended December 31,
	2023	2022
Net Income (Loss)	$660	$(8,485)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments	29	—
Comprehensive Income (Loss)	689	(8,485)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.